Foundation

foundation image

Frontiers In The Development Of Personalised Therapies

Apac Biotech was built on the belief that our immune system is powerful enough to fight cancer from within and now with Apac’s personalised therapies we plan turn the tables on cancer and fight with the cancer patients.

Our flagship product APCEDEN® was the first Indian FDA approved immunotherapy product for the treatment of cancer. Today, our versatile research team of scientists and doctors are going deeper into creating unmatched personalised therapeutics to enhance the immune system further

Our Promise


Our commitment to improve the quality of life of our cancer patients,
their families, drives us in everything we do and
we never give up.

Dedication

  • Dedicated to our patients by enhancing their immunesystem through APCEDEN® (Dendritic cell personalised immunotherapy product) to fight cancer.

  • Enhancing the patient’s immune system by using the patient’s own immune cells ensuring a well tolerated safety profile

The Future

  • Make APCEDEN® personalised immunotherapy available to patient’s in India and around the world

  • Enhancing the technology further to explore the uses of personalised immunotherapy in other cancer treatments.

Our Historical Milestone


  • Preclinical study for Monocyte Derived Dendritic cells and it is validation for its therapeutic value to refractory cancer patients.

    2009
  • Completion of Trial

    July
    2012
  • Trial Results were concluded.

    Oct
    2012
  • APAC made presentation at European Socity of Medical Oncology Conference at Vienna ,Austria.

    Oct
    2012
  • APAC is conferred with the Excellence award for DC clinical trial at UAE Cancer Congress at Dubai.

    Oct
    2012
  • 1st Scientific Review Board consisting of Independent experts and renowned scientist of the country met at Gurgaon to Review the research projects of APAC Biotech.

    Feb
    2013
  • APAC presented the phase 2 data before the CBBTDEC (Cell Biology Based Therapeutic Drug evalution Committee) , A Scientific expert Committee of Drugs Control Department of india which looks after stem cell and other cell based therapies.

    May
    2013
  • Govt of india , forms a high power committee to recommend guidelines for the Dendritic cell therapy and other stem cell therapy.This was only due to constant efforts of APAC that Government of India had to form such committee.

    Jun
    2013
  • Trial result published in peer reviewed Journal ISCT (International Society Of Cellular Therapies)

    Jan
    2014
  • An inspection was done at APAC by CDSCO and ICMR(Indian Council of medical Reseach) official to validate the process and facility before approval.

    Oct
    2014
  • Received a letter from CDSCO starting the recommendation of CBBTDEC meeting on 9th December.The Committee had recommended to enhance the number of patients of specific cancer with objective response criteria .

    Dec
    2014
  • APAC Biotech becomes the first indian Biotechnology Company to receive PMS (post marketing study) approval for its dendritic cell based immunotherapy (APCEDEN®) for four indications, ovarian cancer ,lung cancer ,colon cancer and prostate cancer.

    Mar
    2017
  • Recevied NOC from the DCGI for APCEDEN® protocol.

    Sep
    2017
  • Commenced signing agreements with various hospitals for marketing of APCEDEN®

    Dec
    2017

©2017 - 2018 Apac Biotech Pvt Ltd. All Rights Reserved.